Company intelligence / Profile preview

Neoleukin Therapeutics, Inc.

Seattle, Washington, United Statesneoleukin.com ↗

Ownership: Public · NLTX
Employees: ~30
Development stage: Other

Overview

Neoleukin advanced the first-in-human clinical trial of a de novo designed cytokine mimetic, NL–201, targeting immune activation in cancer. The Phase 1 trial evaluated safety and preliminary efficacy both as monotherapy and in combination with pembrolizumab. Additional assets included preclinical-stage programs such as a SARS-CoV–2 decoy and an IL–2/IL–15 inhibitor. As of late 2023, the company ceased independent operations following its merger into Neurogene.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: de novo protein therapeutics/protein engineeringcytokine mimeticsprotein decoys/inhibitors
Industry: Biotech

Partnerships

Merck & Co., for supply/collaboration on pembrolizumab combination arm in the NL‐201 trial

Beyond the preview

Go deeper on Neoleukin Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neoleukin Therapeutics, Inc..